PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?

被引：29
|
作者：
Gettinger, Scott [1 ]
Politi, Katerina [1 ]
机构：
[1] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA
来源：
CLINICAL CANCER RESEARCH | 2016年 / 22卷 / 18期
关键词：
IMMUNE ESCAPE; EXPRESSION; ACTIVATION; MUTATIONS;
D O I：
10.1158/1078-0432.CCR-16-1401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Programmed death axis 1 (PD-1) inhibitors have ushered in a new error of cancer immunotherapeutics for advanced smoking-associated non-small cell lung cancer. Their role in treating EGFR-mutant and ALK-rearranged lung cancer has yet to be determined. (C) 2016 AACR.
引用
收藏
页码：4539 / 4541
页数：3
相关论文
共 50 条
  • [21] PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy
    Zhu, Yixiang
    Zhang, Ye
    Hu, Xingsheng
    Wang, Mingzhao
    Wang, Hongyu
    Liu, Yutao
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (12) : 3557 - 3566
  • [22] PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy
    Yixiang Zhu
    Ye Zhang
    Xingsheng Hu
    Mingzhao Wang
    Hongyu Wang
    Yutao Liu
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 3557 - 3566
  • [23] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
    Akbay, Esra A.
    Koyama, Shohei
    Carretero, Julian
    Altabef, Abigail
    Tchaicha, Jeremy H.
    Christensen, Camilla L.
    Mikse, Oliver R.
    Cherniack, Andrew D.
    Beauchamp, Ellen M.
    Pugh, Trevor J.
    Wilkerson, Matthew D.
    Fecci, Peter E.
    Butaney, Mohit
    Reibel, Jacob B.
    Soucheray, Margaret
    Cohoon, Travis J.
    Janne, Pasi A.
    Meyerson, Matthew
    Hayes, D. Neil
    Shapiro, Geoffrey I.
    Shimamura, Takeshi
    Sholl, Lynette M.
    Rodig, Scott J.
    Freeman, Gordon J.
    Hammerman, Peter S.
    Dranoff, Glenn
    Wong, Kwok-Kin
    CANCER DISCOVERY, 2013, 3 (12) : 1355 - 1363
  • [24] Rh-endostatin Combined With PD-1 inhibitors as Firstline Treatment for EGFR/ALK-Negative, Nonsquamous NSCLC
    Wang, D.
    Feng, Y.
    Wang, H.
    Peng, H.
    Zhang, W.
    Su, W.
    Li, H.
    Hu, B.
    Bai, Y.
    Ma, H.
    Huang, L.
    Zhu, T.
    Qian, H.
    Li, Y.
    Fang, X.
    Ren, B.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S618 - S618
  • [25] Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge
    Ying Yang
    Yongfeng Yu
    Shun Lu
    Science China Life Sciences, 2020, 63 : 1499 - 1514
  • [26] Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge
    Ying Yang
    Yongfeng Yu
    Shun Lu
    Science China(Life Sciences) , 2020, (10) : 1499 - 1514
  • [27] Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge
    Ying Yang
    Yongfeng Yu
    Shun Lu
    Science China(Life Sciences), 2020, 63 (10) : 1499 - 1514
  • [28] Herpes zoster in lung cancer patients treated with PD-1/PD-L1 inhibitors
    Taoka, Masataka
    Ochi, Nobuaki
    Yamane, Hiromichi
    Yamamoto, Takenobu
    Kawahara, Tatsuyuki
    Uji, Emiko
    Kosaka, Youko
    Takeda, Kouhei
    Nagasaki, Yasunari
    Nakanishi, Hidekazu
    Aoyama, Yumi
    Takigawa, Nagio
    TRANSLATIONAL CANCER RESEARCH, 2022, 11 (03) : 456 - 462
  • [29] Utilization of EGFR, ALK, and BRAF Inhibitors in the Treatment of Lung Cancer in Germany
    Rischke, Nikolaj
    Kanbach, Josephine
    Haug, Ulrike
    CANCER REPORTS, 2024, 7 (12)
  • [30] Challenges to Biomarker Testing for PD-1/PD-L1 Checkpoint Inhibitors for Lung Cancer
    Cagle, Philip T.
    Bernicker, Eric H.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2015, 139 (12) : 1477 - 1478
12345